Scientific Literature
April 3, 2023
Effects of the p38-Alpha Kinase Inhibitor Neflamapimod on the Basal Forebrain in Patients, Assessed by Structural MRI
Read MoreDecember 2, 2022
LP102 Effects of the p38α kinase inhibitor neflamapimod on the basal forebrain, as assessed by structural MRI, in Alzheimer’s Disease
15th CTAD LP102 Poster Alam et al December 2nd 2022
Read MoreSeptember 21, 2022
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
Peer-reviewed publication in the journal Nature Communications
Read MoreNovember 10, 2021
OC5 – Effects of the oral p38α kinase inhibitor neflamapimod on motor function (gait) in patients with mild-to-moderate dementia with Lewy bodies (DLB)
14th CTAD Oral Communication OC5 Alam et al November 10th 2021
Read MoreMay 27, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Prins et al: Alzheimer’s Research & Therapy – Published: 27 May 2021
Read MoreDecember 4, 2020
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level
PLOSOne Dec 2020:
Read MoreSeptember 8, 2020
Functions of p38 MAP Kinases in the Central Nervous System
Journal – Frontiers in Molecular Neuroscience. 13:570586, 2020.
Read MoreJuly 31, 2020
P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease
International Journal of Molecular Sciences. 2020; 21(15): 5485.
Read MoreMay 31, 2020
Neuronal deficiency of p38α‐MAPK ameliorates symptoms and pathology of APP or Tau‐transgenic Alzheimer’s mouse models
Journal – The FASEB Journal. 34(7):9628-9649, 2020.
Read MoreMay 29, 2018
Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers
Frontiers in Aging Neuroscience. Volume 10, Article 155, 2018.
Read MoreDecember 6, 2017
Forecasting the Prevalence of Preclinical and Clinical Alzheimer’s Disease in the United States
Alzheimer’s & Dementia. Volume 14, Issue 2, 2018.
Read MoreMarch 31, 2017
Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production
Scientific Reports. Volume 7, No. 45306, 2017.
Read MoreMarch 30, 2017
Aged Dominant Negative p38α MAPK Mice are Resistant to Age-Dependent Decline in Adult-Neurogenesis and Context Discrimination Fear Conditioning
Behavioural Brain Research. 322, 2017.
Read MoreJanuary 31, 2017
Glucose Deficit Triggers Tau Pathology and Synaptic Dysfunction in a Tauopathy Mouse Model
Translational Psychiatry. 1:9, 2017.
Read MoreDecember 15, 2016
Selective Suppression of the α Isoform of p38 MAPK Rescues Late-Stage Tau Pathology
Alzheimer’s Research & Therapy. 8:54, 2016.
Read MoreNovember 1, 2016
Targeting Neuronal MAPK14/p38α Activity to Modulate Autophagy in the Alzheimer Disease Brain
Autophagy. Volume 12, No. 12, 2016
Read MoreDecember 9, 2015
Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1
Journal of Biological Chemistry. Volume 291, No. 5, 2016.
Read MoreSeptember 8, 2015
Synapse-Specific IL-1 Receptor Subunit Reconfiguration Augments Vulnerability to IL 1β in the Aged Hippocampus
Proceedings of the National Academy of Sciences of the United States of America. 2015.
Read MoreDecember 11, 2012
p38α Mitogen-Activated Protein Kinase Depletion and Repression of Signal Transduction to Translation Machinery by miR-124 and -128 in Neurons
Molecular and Cellular Biology. Volume 33, No. 1, 2012.
Read MoreAbout EIP
Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.
Contact Us